Analysts Offer Predictions for Globus Medical Q3 Earnings

Key Points

• Zacks Research has lowered its Q3 2025 EPS estimate for Globus Medical to $0.78, down from $0.81, with full-year earnings now expected at $3.44 per share.
• The company reported a Q2 earnings of $0.86 per share, exceeding estimates, and achieving a revenue increase of 18.4% year-over-year.
• Institutional investors hold 95.16% of Globus Medical's stock, reflecting strong confidence in the company amidst recent adjustments to earnings estimates and price targets by various analysts.

Globus Medical, Inc. (NYSE:GMED - Free Report) - Equities research analysts at Zacks Research decreased their Q3 2025 earnings estimates for shares of Globus Medical in a research note issued on Thursday, August 28th. Zacks Research analyst Team now expects that the medical device company will earn $0.78 per share for the quarter, down from their prior estimate of $0.81. The consensus estimate for Globus Medical's current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical's Q1 2026 earnings at $0.80 EPS and Q3 2026 earnings at $0.91 EPS.

Several other research firms have also recently commented on GMED. Morgan Stanley lowered their target price on shares of Globus Medical from $75.00 to $68.00 and set an "overweight" rating for the company in a research note on Tuesday, July 15th. Piper Sandler decreased their price target on Globus Medical from $100.00 to $80.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Barclays reissued an "overweight" rating on shares of Globus Medical in a research note on Tuesday, June 10th. BTIG Research reissued a "neutral" rating on shares of Globus Medical in a research note on Tuesday, May 27th. Finally, JMP Securities reissued a "market perform" rating on shares of Globus Medical in a research note on Tuesday, May 27th. Eight research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $87.64.

Globus Medical Stock Performance

GMED stock traded up $1.64 during trading on Monday, hitting $60.44. The stock had a trading volume of 528,633 shares, compared to its average volume of 1,419,578. The stock has a market cap of $8.16 billion, a price-to-earnings ratio of 23.25, a price-to-earnings-growth ratio of 1.71 and a beta of 1.16. Globus Medical has a 1-year low of $51.79 and a 1-year high of $94.93. The company's 50 day moving average price is $57.76 and its two-hundred day moving average price is $65.00.

Globus Medical (NYSE:GMED - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical device company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.10. Globus Medical had a net margin of 13.58% and a return on equity of 10.65%. The firm had revenue of $745.34 million during the quarter, compared to the consensus estimate of $738.91 million. During the same quarter in the previous year, the company posted $0.75 EPS. The firm's revenue for the quarter was up 18.4% on a year-over-year basis.

Globus Medical declared that its Board of Directors has approved a stock repurchase program on Thursday, May 15th that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the medical device company to buy up to 6.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GMED. Invesco Ltd. grew its holdings in shares of Globus Medical by 331.9% during the first quarter. Invesco Ltd. now owns 2,021,156 shares of the medical device company's stock valued at $147,949,000 after buying an additional 1,553,154 shares in the last quarter. Norges Bank purchased a new stake in shares of Globus Medical during the second quarter worth $68,038,000. RTW Investments LP bought a new stake in Globus Medical in the fourth quarter worth $80,394,000. Iron Triangle Partners LP bought a new stake in Globus Medical in the fourth quarter worth $69,808,000. Finally, Polar Capital Holdings Plc bought a new stake in Globus Medical in the fourth quarter worth $63,762,000. Hedge funds and other institutional investors own 95.16% of the company's stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.